Authors' Reply

Sudeep Gupta; Rajendra A. Kerkar; Rajesh Dikshit; Rajendra A. Badwe

doi:10.4103/2278-330x.126580

View/Download PDF

Buy Reprints

PDF

Translate this page into:

Letter to Editor

03 (

01

); 094-095

doi:

10.4103/2278-330x.126580

Authors' Reply

Sudeep Gupta^1,, Rajendra A. Kerkar², Rajesh Dikshit³, Rajendra A. Badwe¹

1 Departments of Medical Oncology, Parel, Mumbai, Maharashtra, India

2 1Surgical Oncology, Parel, Mumbai, Maharashtra, India

3 Epidemiology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India

*Corresponding author: Dr. Sudeep Gupta. sudeepgupta04@yahoo.com

Published: 2020-12-31

MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.

References

Palefsky J. HPV vaccination in India.South Asian J Cancer 2014;3:96-7.
Gupta S, Kerkar RA, Dikshit R, Badwe RA. Is human papillomavirus vaccination likely to be a useful strategy in India? South Asian J Cancer 2013;2:193-7.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
Vidal AC, Smith JS, Iversen E, Valea F, Bentley R, Gradison M, et al. HPV genotype distribution and cervical intraepithelial neoplasia in African-American and white women living in the southeastern United States. AACR-FCPR 2013; Abstract B11, PR01.
Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the Quadrivalent Human Papillomavirus Vaccine Against Cervical Dysplasia in Manitoba, Canada. J Clin Oncol 2014;32:1-7.
Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F. Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: An age-period-cohort analysis. Br J Cancer 2011;105:723-30.
Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_ population.aspx. [Last accessed 2013 Dec 30].
Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: Design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-4611.
Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, et al. Guillain-Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011;29:886-9.
Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
Shastri SS, Mittra I, Mishra G, Gupta S, Dikshit R, Badwe RA. Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India. J Clin Oncol. 2013;31(suppl; abstr 2).

Fulltext Views
33

PDF downloads
3

View/Download PDF
Download Citations

BibTeX
RIS

Show Sections

[1] Palefsky J. HPV vaccination in India.South Asian J Cancer 2014;3:96-7.

[2] Gupta S, Kerkar RA, Dikshit R, Badwe RA. Is human papillomavirus vaccination likely to be a useful strategy in India? South Asian J Cancer 2013;2:193-7.

[3] FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.

[4] Vidal AC, Smith JS, Iversen E, Valea F, Bentley R, Gradison M, et al. HPV genotype distribution and cervical intraepithelial neoplasia in African-American and white women living in the southeastern United States. AACR-FCPR 2013; Abstract B11, PR01.

[5] Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the Quadrivalent Human Papillomavirus Vaccine Against Cervical Dysplasia in Manitoba, Canada. J Clin Oncol 2014;32:1-7.

[6] Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F. Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: An age-period-cohort analysis. Br J Cancer 2011;105:723-30.

[7] Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_ population.aspx. [Last accessed 2013 Dec 30].

[8] Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: Design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-4611.

[9] Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, et al. Guillain-Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011;29:886-9.

[10] Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.

[11] Shastri SS, Mittra I, Mishra G, Gupta S, Dikshit R, Badwe RA. Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India. J Clin Oncol. 2013;31(suppl; abstr 2).